Prostate Cancer Working Group
Advances in imaging, molecular phenotyping, precision biomarkers, and expanding therapeutics present new opportunities and challenges in the treatment of advanced prostate cancer. Composed of international leaders across clinical oncology, translational science, nuclear medicine, radiology, and biostatistics, the Prostate Cancer Working Group (PCWG) was formed to create a collaborative clinical and research culture aligned around optimizing trial design and therapeutic development for patients with prostate cancer. In its most recent iteration, PCWG4 updated recommendations on patient and tumor characterization, disease state terminology, imaging criteria including PSMA-PET, biomarker-based eligibility, and patient-reported outcomes, extending guidance into earlier androgen pathway modulator–naïve and –sensitive disease states. PCWG members work to develop rigorous, evidence-based standards for clinical trial conduct that reflect the evolving, heterogeneous, and diverse prostate cancer patient population, with the ultimate goal of maximizing survival and quality-of-life benefits for all patients most likely to benefit from emerging therapies.
Publications
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
- Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group